教育背景
2010-2016 MD Anderson Cancer Center 肿瘤生物学 博士
2005-2010 南方医科大学 医学学士
工作经历
2024- 清华大学基础医学院 副教授
2019-2024 清华大学医学院 助理教授
2016-2019 哈佛医学院 博士后
研究领域和科学贡献
肿瘤对治疗耐药，尤其是对免疫治疗不响应是亟待解决的临床难题。潘登博士长期致力于肿瘤免疫逃逸机制与原创肿瘤治疗靶点发现研究。潘登实验室通过研究肿瘤免疫逃逸的分子机制，进而识别新的肿瘤免疫治疗靶点。实验室利用前沿的功能基因组学工具，结合多种体内外筛选平台，系统解析肿瘤细胞如何逃避免疫系统中不同类型效应细胞的清除——包括 CD8+ T 细胞（Cell Metab., 2023；Immunity, 2025；J Exp Med., 2025；Cell Rep Med., 2025）、NK 细胞（Cancer Res., 2025）以及巨噬细胞（J Clin Invest., 2025）。实验室还开发了针对多类肿瘤浸润免疫细胞的功能筛选体系，覆盖主要的淋巴系与髓系细胞谱系。通过在肿瘤细胞与免疫细胞中结合遗传扰动研究，潘登实验室旨在构建全面的免疫逃逸机制图谱，并将这些发现转化为创新且有效的肿瘤免疫治疗策略。
荣誉奖励
2019 国家青年人才计划
2019 拜耳研究员
代表性论文
PI时期代表性论文 (#代表通讯作者)
Zhao J, Li X, Li X, Ren P, Wu Y, Gong H, Wu L, Huang J, Wang S, Guo Z, Chen M#, Zeng Z# and Pan D#. Targeting plasticity in the pyrimidine synthesis pathway potentiates macrophage-mediated phagocytosis in pancreatic cancer models. J Clin Invest., 2025 Nov 17;135(22):e193370. doi: 10.1172/JCI193370.
Wang H, Zhao F, Li Y, Wang P, Wang Y, Ren P, Li C, Zheng H, Zeng Z#, and Pan D#. ZNF296 Drives Immune Evasion in Epithelial Cancers by Repressing Immune Stimulatory Genes. Cancer Res., 2025 Sep 24. doi: 10.1158/0008-5472.CAN-25-0153.
Lu Y, Luo C, Huang L, Wu G, Zhong L, Chu J, Wang F#, Zeng Z# and Pan D#. Functional genetic screens reveal key pathways instructing the molecular phenotypes of tumor-associated macrophages. Cancer Immunol Res., 2025 Sep 4. doi: 10.1158/2326-6066.CIR-25-0488.
Tang K, Wu L#, Hu Y, Xue T, Jin Y, Zhou X, Luo C, Zhao Y, Tong L, Dai J, Feng D, Zeng Z# and Pan D#. Perturbation of Calreticulin potentiates CD8+ T cell-mediated anti-tumor immunity. Journal of Experimental Medicine, 2025 Oct 6;222(10):e20242360. doi: 10.1084/jem.20242360.
Zhou X, Xu T, Li C, He Y, Hu Y, Gong H, Li J, Jiang H, Wen L, Fu Y, Zeng Z#, Pan D#. Potentiating anti-tumor immunity by re-engaging immune synapse molecules. Cell Reports Medicine, Feb 14:101975. doi: 10.1016/j.xcrm.2025.101975.
Luo C, Zhang R, Guo R, Wu L, Xue T, He Y, Jin Y, Zhao Y, Zhang Z, Zhang P, Ye S, Li X, Li D, Zhang W, Wang C, Lai L, Pan-Hammarström Q, Wucherpfennig KW, Gao Z#, Pan D#, Zeng Z# Integrated computational analysis identifies therapeutic targets with dual action in cancer cells and T cells. Immunity, 2025 Mar 11;58(3):745-765.e9. doi: 10.1016/j.immuni.2025.02.007.
Wu L, Jin Y, Zhao X, Tang K, Zhao Y, Tong L, Yu X, Xiong K, Luo C, Zhu J, Wang F#, Zeng Z#, Pan D#. Tumor aerobic glycolysis confers immune evasion through modulating sensitivity to T cell-mediated bystander killing via TNFa. Cell Metabolism, 2023 Sep 5;35(9):1580-1596.e9. doi: 10.1016/j.cmet.2023.07.001.
博士后和学生时期代表性论文
Ito Y*, Pan D*, Zhang W, Zhang X, Juan TY, Pyrdol JW, Kyrysyuk O, Doench JG, Liu XS, Wucherpfennig KW. Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell-Secreted Cytokines. Cancer Discovery 2023 May 4;13(5):1186-1209. doi: 10.1158/2159-8290.CD-22-1125. (* Denotes equal contribution)
Pan D*, Kobayashi A*, Jiang P*, Andrade LF, Tay RE, Luoma A, Tsoucas D, Qiu X, Lim K, Rao P, Long HW, Yuan G, Doench J, Brown M, Liu XL, and Wucherpfennig KW. A Major Chromatin Regulator Determines Resistance of Tumor cells to T cell Mediated Killing. Science, 2018 Jan 4; pii:eaao1710 doi: 10.1126/science.aao1710. (* Denotes equal contribution)
Jiang P*, Gu S*, Pan D*, Fu J, Li Z, Bu X, Li B, Liu JS, Freeman G, Brown M, Wucherpfennig KW and Liu XL. Signatures of T-cell dysfunction and exclusion predict cancer immunotherapy response. Nature Medicine, 2018 Oct;24(10):1550-1558. (* Denotes equal contribution)
Pan D, Jiang C, Ma Z, Blonska M, You MJ and Lin X. The role of MALT1 in EGFR induced NF-kappaB activation and EGFR associated lung cancer progression. Oncogene. 2016 Feb 18; 35(7):919-28.
Pan D*, Zhu Y*, Zhou Z, Wang T, You H, Jiang C and Lin X. CARMA3-BCL10-MALT1 -mediated NF-kB activation contributes to HRE2-assocaited tumor malignancy in breast cancer. Molecular Cancer Research 2016 Jan ;14(1):93-102. (* denotes equal contribution)
联系方式：
E-mail: dpan[AT]tsinghua.edu.cn
地址：北京市海淀区清华大学医学科学楼B115
实验室网站：https://www.pan-lab-at-tsinghua.com
